- Pivotal Phase 3 data showed the potential of Ferric Citrate (Auryxia®) to treat IDA in adults with NDD-CKD
- Phase 3 trial results support supplemental new drug application (sNDA) seeking to expand Auryxia's label
Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.
Shares of Omeros fell almost 10% after analysts' downgraded the biotech.
Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "perilous reversal" (up big yesterday but down big today) candidate